Author:
Bakris George L.,Townsend Raymond R.,Liu Minglei,Cohen Sidney A.,D’Agostino Ralph,Flack John M.,Kandzari David E.,Katzen Barry T.,Leon Martin B.,Mauri Laura,Negoita Manuela,O’Neill William W.,Oparil Suzanne,Rocha-Singh Krishna,Bhatt Deepak L.
Subject
Cardiology and Cardiovascular Medicine
Reference22 articles.
1. U.S. Food and Drug Administration. Guidance for Industry Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims. 2011. Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm. Accessed May 23, 2014.
2. National Clinical Guideline Centre. Hypertension: The Clinical Management of Primary Hypertension in Adults. Clinical Guideline 127: Methods, Evidence and Recommendations: National Institute for Health and Clinical Excellence. 2011:328.
3. Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial;Bakris;Hypertension,2010
4. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study;Krum;Lancet,2014
5. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial;Esler;Circulation,2012
Cited by
155 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献